AIM: This study attempted to identify predictors of S-warfarin clearance (CL[S]) and to make a pharmacokinetic evaluation of genotype-based dosing algorithms in African-Americans. METHODS: Using plasma S-warfarin concentration (Cp[S]) at a steady state and eight SNPs previously shown to influence warfarin dose in African-Americans, CL(S) and its predictors were estimated by population pharmacokinetic analysis in 60 African-Americans. The time courses of Cp(S) following either the loading dose or maintenance dose were simulated using the population pharmacokinetic estimates. RESULTS: CYP2C9*8 and body surface area or body weight were predictors of CL(S) (-30 and -5% per -0.1 m(2)/-10 kg reduction in CL[S], respectively) in African-Americans. Simulations of Cp(S) showed that Cp(S) at steady state was 1.4-times higher in patients with CYP2C9*8 than in those with CYP2C9*1/*1, irrespective of the algorithm for loading dose or maintenance dose. CONCLUSION: African-Americans possess independent predictors of CL(S), possibly leading to a prediction error of any dosing algorithm that excludes African-specific variant(s). Original submitted 3 September 2014; Revision submitted 3 November 2014.
AIM: This study attempted to identify predictors of S-warfarin clearance (CL[S]) and to make a pharmacokinetic evaluation of genotype-based dosing algorithms in African-Americans. METHODS: Using plasma S-warfarin concentration (Cp[S]) at a steady state and eight SNPs previously shown to influence warfarin dose in African-Americans, CL(S) and its predictors were estimated by population pharmacokinetic analysis in 60 African-Americans. The time courses of Cp(S) following either the loading dose or maintenance dose were simulated using the population pharmacokinetic estimates. RESULTS:CYP2C9*8 and body surface area or body weight were predictors of CL(S) (-30 and -5% per -0.1 m(2)/-10 kg reduction in CL[S], respectively) in African-Americans. Simulations of Cp(S) showed that Cp(S) at steady state was 1.4-times higher in patients with CYP2C9*8 than in those with CYP2C9*1/*1, irrespective of the algorithm for loading dose or maintenance dose. CONCLUSION: African-Americans possess independent predictors of CL(S), possibly leading to a prediction error of any dosing algorithm that excludes African-specific variant(s). Original submitted 3 September 2014; Revision submitted 3 November 2014.
Authors: Y Liu; H Jeong; H Takahashi; K Drozda; S R Patel; N L Shapiro; E A Nutescu; L H Cavallari Journal: Clin Pharmacol Ther Date: 2012-02-29 Impact factor: 6.875
Authors: A-K Hamberg; M Wadelius; J D Lindh; M L Dahl; R Padrini; P Deloukas; A Rane; E N Jonsson Journal: Clin Pharmacol Ther Date: 2010-04-21 Impact factor: 6.875
Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Christina L Aquilante; Taimour Y Langaee; Larry M Lopez; Hossein N Yarandi; Jennifer S Tromberg; Dagmara Mohuczy; Katherine L Gaston; Cassandra D Waddell; Mark J Chirico; Julie A Johnson Journal: Clin Pharmacol Ther Date: 2006-02-28 Impact factor: 6.875
Authors: Roxana Daneshjou; Eric R Gamazon; Ben Burkley; Larisa H Cavallari; Julie A Johnson; Teri E Klein; Nita Limdi; Sara Hillenmeyer; Bethany Percha; Konrad J Karczewski; Taimour Langaee; Shitalben R Patel; Carlos D Bustamante; Russ B Altman; Minoli A Perera Journal: Blood Date: 2014-07-30 Impact factor: 22.113
Authors: T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson Journal: N Engl J Med Date: 2009-02-19 Impact factor: 91.245
Authors: K Kubo; M Ohara; M Tachikawa; L H Cavallari; M T M Lee; M S Wen; M G Scordo; E A Nutescu; M A Perera; A Miyajima; N Kaneko; V Pengo; R Padrini; Y T Chen; H Takahashi Journal: Pharmacogenomics J Date: 2016-08-09 Impact factor: 3.550
Authors: Minami Ohara; Yasuhiko Suzuki; Saki Shinohara; Inna Y Gong; Crystal L Schmerk; Rommel G Tirona; Ute I Schwarz; Ming-Shien Wen; Ming Ta Michael Lee; Kiyoshi Mihara; Edith A Nutescu; Minoli A Perera; Larisa H Cavallari; Richard B Kim; Harumi Takahashi Journal: Clin Pharmacokinet Date: 2019-08 Impact factor: 6.447
Authors: Aditi Shendre; Todd M Brown; Nianjun Liu; Charles E Hill; T Mark Beasley; Deborah A Nickerson; Nita A Limdi Journal: Pharmacotherapy Date: 2016-03-14 Impact factor: 4.705